"Providing specialized cancer care treatments and clinical trials on the Gold Coast."

During the past decade, Tasman Oncology Research conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 7 clinical trials were completed, i.e. on average, 63.6% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 6 clinical trials were completed. i.e. 85.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tasman Oncology Research" #1 sponsor was "Amgen" with 2 trials, followed by "BeiGene" with 2 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tasman Oncology Research" #1 collaborator was "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Tasman Oncology Research" are "Melanoma" (2 trials), "Neoplasm Metastasis" (2 trials), "Solid Tumors" (2 trials), "Abiraterone Acetate" (1 trials) and "Adenoid Cystic Carcinoma" (1 trials). Many other conditions were trialed in "Tasman Oncology Research" in a lesser frequency.

Most popular intervention types in "Tasman Oncology Research" are "Drug" (12 trials) and "Biological" (5 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (4 trials), "Nivolumab" (2 trials), "Abemaciclib" (1 trials), "Abiraterone" (1 trials) and "Avelumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tasman Oncology Research" are 13 trials for "All" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Tasman Oncology Research". undefined are not yet recruiting, 3 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Tasman Oncology Research, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Tasman Oncology Research, 7 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".